The present disclosure provides methods for determining signatures of immune responses to immunomodulating agents in cells and in tissues. Also provided herein are computational methods for deconvoluting gene expression profiling data. Further provided herein are methods for treating a disease or disorder (e.g, proliferative diseases such as cancer, autoimmune diseases such as rheumatoid arthritis and psoriasis, allergies, etc.) in a subject comprising administering one or more immunomodulating agents to drive an immune response, in combination with a treatment for the disease or disorder (e.g, an anti-cancer therapy, an anti-viral therapy, a vaccination, etc.).

A process is provided for inhibiting symptoms of celiac disease, Clostridium difficile associated diseases such as Clostridium difficile colitis, pseudomembranous colitis and antibiotic associated diarrhea, food allergy or food intolerance in a subject that includes the oral administration to the subject suffering from food allergy or food intolerance an IgM. When administered in a, therapeutic quantity based on the subject characteristics and the type of IgM, symptoms of food allergy or food intolerance in that subject are inhibited. Even non-secretory forms of IgM are effective when administered orally.

The present application relates to compositions for oral immunotherapy of peanut allergies. Further, the present application relates to methods for the preparation of the compositions for immunotherapy, and their use in immunotherapy.

Compositions and methods for the treatment of autoimmune and inflammatory diseases are disclosed.

The present invention relates to a purified veterinary allergen extract enriched. In particular, the invention relates to a purified veterinary allergen extract enriched with Der f 15 and Der f 18. The invention further relates to use of the allergen extract as a veterinary product, and its use in treating allergy, in particular house dust mite allergy in mammals, more particularly, dogs.

The invention relates to compositions and methods for treating inflammatory diseases and disorders in a subject in need thereof. In certain aspects, the invention relates to immunogenic compositions (e.g., vaccines) to diminish the number or pathogenic effects of one or more bacteria associated with the development or progression of an inflammatory disease or disorder.

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.

Baby food products containing allergenic protein and methods of delivering the products are provided as a source of early introduction for prevention of food allergy in children. The product may be a solid or semi-solid product and includes an allergenic protein, one or more of a prebiotic or a probiotic, and a foodstuff. A method of feeding a baby food product to a child involves providing the child with a serving of the baby food product such that the child ingests a pre-defined amount of an allergenic protein. The serving may be provided on a periodic basis such that the child ingests a constant amount of the allergenic protein per week over an extended period.

Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.

The present invention relates to a method for enhancing the ability of regulatory T cells (Tregs) to suppress immune responses comprising increasing FOXP3 expression in a population of Tregs.